Accessibility Menu
Diagnos logo

Diagnos(TSXV) ADK

Market CapCA$33.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)-99%
5 Year-52%
1 Year+20%
1 Month+10%
CA$0.28
+0.00%
+0.00Today
Diagnos last closing stock price
MetricPriceDate
Last closeCAD 0.282026-07-31
Diagnos stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+14.58%CAD 0.242026-07-24
1 month+10%CAD 0.252026-06-30
3 month+19.57%CAD 0.232026-05-01
Year to date-26.67%CAD 0.382025-12-31
1 year+19.57%CAD 0.232025-07-31
3 year-36.78%CAD 0.442023-08-01
5 year-51.75%CAD 0.572021-07-30
Since inception-99.47%CAD 52.002000-11-30

Diagnos Financials at a Glance

Market Cap

CA$33.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$65.48K

Net Income (TTM)

-CA$4.56M

EPS (TTM)

-CA$0.04

P/E Ratio

-6.64

Dividend

CA$0.00

Beta (Volatility)

-0.06 (Low)

Price

CA$0.28

Volume

63,149

Open

CA$0.29

Previous Close

CA$0.28

Daily Range

CA$0.28 - CA$0.29

52-Week Range

CA$0.18 - CA$0.42

Estimated Earnings Date

Aug 24, 2026

ADK News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Diagnos

DIAGNOS Inc. is a technology firm specializing in software-based services within the healthcare sector. The company focuses on early detection of diabetic retinopathy through its advanced Computer Assisted Retina Analysis (CARA) platform, while also offering consulting services in data analytics and artificial intelligence.

Products and Services
  • Computer Assisted Retina Analysis (CARA) for diabetic retinopathy detection
  • Consulting services in data analytics and artificial intelligence
  • International operations across multiple countries including Canada and the U.S.
Growth Outlook
  • Expansion into new international markets is underway
  • Increased demand for AI-driven healthcare solutions is anticipated
  • Focus on enhancing CARA technology to improve user experience
Financial Highlights
  • Recent quarterly revenue of CAD 15,711, showing consistent performance
  • Trailing twelve months (TTM) net income margin of -69.57%, indicating operational challenges
  • Current ratio of 1.49 suggests adequate short-term financial health
DIAGNOS Inc. operates in a niche market with significant growth potential, particularly in the healthcare technology sector. The CARA platform is positioned to address a critical need for early detection of diabetic retinopathy, a condition affecting millions globally. Despite facing operational challenges reflected in the negative net income margin, the company maintains a solid current ratio, indicating it can meet its short-term obligations. The ongoing expansion into international markets and the increasing demand for AI-driven solutions present opportunities for future growth. Investors may find the company's innovative approach and market positioning noteworthy as it navigates the evolving landscape of healthcare technology.
AI Generated • Jul 9, 2026

Industry

Health Care Technology

Sector

Health Care

CEO

André M. Larente

Website

www.diagnos.com

Headquarters

Brossard, QC J4Z 1A7, CA

ADK Financials

Key Financial Metrics (TTM)

Gross Margin

-182.42%

Operating Margin

-6510.52%

Net Income Margin

-6956.84%

Return on Equity

11659.44%

Return on Capital

-204.11%

Return on Assets

-190.55%

Earnings Yield

-15.06%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$33.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

120.41M

Volume

63.15K

Avg. Volume

240.37K

Financials (TTM)

Gross Profit

-CA$119.45K

Operating Income

-CA$4.26M

EBITDA

-CA$4.09M

Operating Cash Flow

-CA$3.86M

Capital Expenditure

-CA$11.07K

Free Cash Flow

-CA$3.87M

Cash & ST Invst.

CA$1.93M

Total Debt

CA$1.40M

Diagnos Performance Analysis

Diagnos annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31CAD 485,74910.7%
20242024-03-31CAD 170,158-65.0%
20252025-03-31CAD 103,797-39.0%
20262026-03-31CAD 65,478-36.9%
Diagnos sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-305.5%
Q22025-09-30-21.9%
Q32025-12-310.3%
Q42026-03-313.3%
Diagnos annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31CAD -0.04-6.3%
20242024-03-31CAD -0.0420.2%
20252025-03-31CAD -0.0513.6%
20262026-03-31CAD -0.04-13.2%
Diagnos sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-3016.8%
Q22025-09-301.8%
Q32025-12-317.5%
Q42026-03-311.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

CA$15.71K

-14.6%

Gross Profit

CA$1.02M

+449.8%

Gross Margin

64.63%

N/A

Market Cap

CA$33.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$2.07M

N/A

Employees

16

N/A

Net Income

-CA$1.18M

+11.4%

EBITDA

-CA$1.15M

+0.2%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

CA$1.93M

-40.4%

Total Debt

CA$1.40M

-54.4%

Accounts Receivable

CA$194.86K

+27.8%

Inventory

CA$0.00

N/A

Long Term Debt

CA$225.71K

-21.1%

Short Term Debt

CA$1.18M

-57.8%

Return on Assets

-1.91%

N/A

Return on Invested Capital

-4.67%

N/A

Free Cash Flow

-CA$1.31M

-5.7%

Operating Cash Flow

-CA$1.31M

-5.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RVX.TOResverlogix Corp.
CA$0.10-5.00%
LABS.TOMediPharm Labs Corp.
CA$0.08+0.00%
ROMJ.VRubicon Organics Inc.
CA$0.47+4.44%
MBX.TOMicrobix Biosystems Inc.
CA$0.30-1.67%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.36+0.02%
PLTRPalantir Technologies
$125.65+0.02%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$23.99+0.01%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$41.43-0.05%

Questions About ADK

What is the current price of Diagnos?

Diagnos is trading at CA$0.28 per share.

What is the 52-week range for Diagnos?

Over the past 52 weeks, Diagnos has traded between CA$0.18 and CA$0.42.

How much debt does Diagnos have?

As of the most recent reporting period, Diagnos reported total debt of CA$1.40M.

How much cash does Diagnos have on hand?

Diagnos reported CA$310.01K in cash and cash equivalents in its most recent financial results.

What is Diagnos’s dividend yield?

Diagnos does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services